



Ext. Glensmo.
ff
6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:) Group Art Unit: 1644
Jihoon CHANG et al.) Examiner: Maher Haddad
Serial No.: 10/088,548)
Filed: March 15, 2002)
For: A NOVEL ANGIOGENESIS INHIBITOR)

)

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

JAN 21 2003

TECH CENTER 1600/2900

RESPONSE TO THE RESTRICTION REQUIREMENT

Sir:

In response to the Office Action dated November 5, 2002 in connection with the above-identified application, please enter the following Response to the Restriction Requirement.

REMARKS

In the Office Action of November 5, 2002, the Examiner has divided the claims into twenty-two (22) groups: Group I (claims 1 and 17), drawn to LK6 protein; Group II (claims 2 and 17), drawn to LK7 protein; Group III (claims 3 and 17), drawn to LK8 protein; Group IV (claims 4 and 17), drawn to LK68 protein; Group V (claims 5,9 and 13), drawn to a cDNA sequence which codes for the LK6 protein; Group VI (claims 6,10 and 14), drawn to a cDNA sequence which codes for the LK7 protein; Group VII (claims 7,11 and 15), drawn to a cDNA sequence which codes for the LK8 protein; Group VIII (claims 8,12 and 16), drawn to a cDNA

CERTIFICATE OF MAILING

(37 C.F.R. § 1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

01/17/2003 GGEBREGI 00000042 10088548

01 FC:2251

55.00 OP

Joseph Kim

Name of Person Mailing Paper

January 6, 2003

Date of Deposit



Signature of Person Mailing Paper